CDR-Life Breakthrough with M-gager® Innovations for Cancer Therapies

Author: Olivia Taylor Updated: 09-14-2024 06:34 AM

CDR-Life Announces Significant Progress in Cancer Treatment

CDR-Life has recently made headlines with its innovative approach to combating solid tumors through the M-gager® antibody fragment technology. This advancement comes as part of the company's commitment to developing cutting-edge immunotherapies for cancers that are challenging to treat.

Patient Dosing Milestone for CDR404

In an exciting development, the first patient has been dosed with CDR404. This innovative treatment is a bispecific and bivalent T cell engager (TCE) specifically designed to target MAGE-A4, a protein that is often associated with various cancer types. By directing the immune system's attention toward cancer cells that present this specific protein, CDR404 aims to enhance anti-tumor responses.

Clinical Study of CDR404

The ongoing Phase 1 clinical study (NCT06402201) is actively enrolling patients who express HLA-A*02:01 and have MAGE-A4 positive solid tumors. Conducted across multiple sites in Europe and the U.S., this trial investigates CDR404's safety, tolerability, and preliminary anti-tumor efficacy in several common cancers, including squamous cell carcinomas, which are known to have high levels of MAGE-A4 expression.

Introduction of CDR813 for PRAME Targeting

CDR-Life is also advancing an exciting new clinical candidate, CDR813, which targets the Preferentially Expressed Antigen in Melanoma (PRAME). This tumor-specific target is expressed across a variety of solid tumors, including those found in the lungs, ovaries, melanoma, and endometrial cancers. Importantly, PRAME is expressed minimally in healthy tissues, allowing for a more selective attack on cancer cells.

Characteristics of CDR813

CDR813 utilizes a bispecific antibody fragment to effectively bind to an HLA-A*02 restricted peptide derived from PRAME on the surface of cancer cells. According to pre-clinical studies, CDR813 has demonstrated strong pharmacological properties and manufacturability, setting the stage for a promising clinical future.

Upcoming ESMO Congress Poster Presentation

In a commitment to share their findings with the broader medical community, CDR-Life will be presenting a poster at the upcoming European Society for Medical Oncology (ESMO) Congress. The poster titled “Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01” will showcase their groundbreaking work and ongoing research.

Poster Presentation Details

Details about the poster presentation are as follows:
Title: Highly potent and specific bivalent T cell engager targeting PRAME
Date and Time: A scheduled presentation on Saturday, September 14, 2024, from 12 – 1 pm CET
Abstract Number: 5132, Poster 1020P

CDR-Life's Vision for Cancer Therapies

Swethajit Biswas, the Chief Medical Officer at CDR-Life, expressed enthusiasm regarding the advancements of CDR404 and the potential of CDR813. He highlighted the significance of these milestones in their pursuit to engineer transformative antibody fragment-based treatments for patients with the HLA-A*02:01 genotype, which is prevalent in many regions including the U.S. and Europe.

With a strong focus on solid tumor oncology, CDR-Life aims to create a robust pipeline of highly specific and potent molecules that target a wide range of cancer-specific antigens. This innovative approach seeks to address critical areas of cancer treatment, especially those involving proteins associated with tumor growth.

About CDR-Life

CDR-Life is dedicated to developing targeted T cell engagers for solid cancers and autoimmune diseases. Their M-gager® platform showcases their commitment to delivering therapies that specifically target cancer-related intracellular and surface antigens. The partnership with Boehringer Ingelheim on a molecule from the M-gager® platform, now moving into Phase 2 clinical trials, illustrates the promising potential of their novel therapies. CDR-Life is steadfast in its goal to provide innovative and effective solutions for patients around the globe.

Frequently Asked Questions

What is the M-gager® technology?

The M-gager® technology is a platform developed by CDR-Life to create highly specific T cell engagers targeting cancer-specific antigens, enhancing therapeutic efficacy.

What are CDR404 and CDR813?

CDR404 and CDR813 are novel T cell engagers designed to target MAGE-A4 and PRAME, respectively, aimed at treating solid tumors in patients.

Where is the clinical trial for CDR404 being conducted?

The clinical trial for CDR404 is being conducted at multiple sites across the U.S. and Europe.

What is PRAME, and why is it important?

PRAME is a tumor-specific antigen expressed in various solid tumors, making it an important target for developing selective cancer therapies.

When will CDR-Life present their findings?

CDR-Life will present their findings at the ESMO Congress on September 14, 2024.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.